Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site
Hidetoshi Hayashi(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kazuto Nishio(Kindai University Sakai Hospital), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Yuichi Takiguchi(Sanno Medical Center), Yosuke Togashi(Okayama University), Shin Takahashi(Institute of Aging), Shuta Tomida(Okayama University), Hisateru Yasui(Kobe City Medical Center General Hospital), Yusuke Onozawa(Shizuoka Cancer Center), Koji Matsumoto(Showa University), Chihiro Kondoh(Toranomon Hospital), Toshiyuki Sawa(Kite (United States)), Hironobu Minami(Kobe University), Hiroki Ueda(Wakayama Medical University), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Yoshihiko Segawa(Saitama Medical University), Kohei Akiyoshi(Osaka City General Hospital), Yoshihiko Fujita(Kyoto University)
Cited by 119
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k